Equities research analysts expect TherapeuticsMD Inc (NASDAQ:TXMD) to post ($0.11) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for TherapeuticsMD’s earnings. TherapeuticsMD also reported earnings per share of ($0.11) in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Wednesday, November 2nd.
According to Zacks, analysts expect that TherapeuticsMD will report full year earnings of $0.00 per share for the current financial year. For the next year, analysts forecast that the firm will post earnings of $0.00 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $5.63 million. The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.16) EPS.
Several research analysts have weighed in on TXMD shares. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, September 3rd. Jefferies Group reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Wednesday, June 8th. Finally, Noble Financial reaffirmed a “buy” rating and set a $17.50 target price on shares of TherapeuticsMD in a research note on Monday, July 11th.
TherapeuticsMD (NASDAQ:TXMD) opened at 6.81 on Monday. The company’s 50-day moving average is $6.80 and its 200-day moving average is $7.64. The company’s market cap is $1.34 billion. TherapeuticsMD has a 12 month low of $5.18 and a 12 month high of $11.26.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.